SunOpta Raises FY25 Adjusted EBITDA Outlook to $94M-$95M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Consensus $813.72M. Raises FY25 adjusted EBITDA view to $94M-$95M from $90M-$92M. "We are raising our fiscal 2025 outlook. On our third-quarter earnings call in early November, we outlined short-term incremental costs and near-term initiatives to strengthen our supply chain while managing exceptional volume growth. While we had a challenging October, we delivered results above expectations in November and December, driving fourth-quarter profitability that is significantly better than what we anticipated two months ago," said Brian Kocher, CEO of SunOpta. "This progress certainly reinforces our confidence in the previously provided outlook for 2026. We will provide more details on our 2026 outlook when we release our fourth-quarter and fiscal 2025 results, which we expect will be in early March."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STKL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STKL
Wall Street analysts forecast STKL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STKL is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.580
Low
8.00
Averages
8.00
High
8.00
Current: 4.580
Low
8.00
Averages
8.00
High
8.00
About STKL
SunOpta Inc. operates as a partner, solutions provider and value-added manufacturer for various brands, and produces its own brands, including SOWN, Dream and West Life. The Company is focused on organic, non-genetically modified (non-GMO) and specialty foods. The Company's product categories include fruit-based snacks, plant-based beverages, plant-based ingredients, broth and stock, and liquid packaged and bulk tea concentrate. Its fruit-based snacks include fruit bars, bits, twists, strips, and pressed bars and strips. The Company's plant-based beverages include oat milk, soymilk, almond milk, coconut milk, hemp milk, and other nut, grain, seed & legume-based beverages. Its plant-based ingredients include oat base and soy base. It sells its products through various distribution channels, including foodservice operators, grocery retailers and club stores, branded food companies, and food manufacturers, located principally in the United States, as well as e-commerce channels.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Stocks Mixed; Day One Biopharmaceuticals Shares Surge 20%
- Mixed Market Performance: U.S. stocks exhibited mixed results on Monday, with the Nasdaq Composite gaining over 50 points and rising 0.29%, while the Dow Jones fell 0.19% to 49,411.94, indicating market volatility and investor caution.
- Biopharma Surge: Day One Biopharmaceuticals Inc (NASDAQ:DAWN) shares surged 20% to $10.77 after reporting a projected 2025 OJEMDA net product revenue of $155.4 million, a 172% year-over-year increase, highlighting strong market demand and growth potential.
- FDA Response Impact: Atara Biotherapeutics Inc (NASDAQ:ATRA) shares plummeted 53% to $6.41 following a Complete Response Letter from the FDA citing concerns over clinical trial adequacy, raising investor worries about the company's future prospects.
- Sector Sentiment Fluctuations: Financial stocks dipped by 1.1% while consumer staples rose by 1%, reflecting differing investor confidence across sectors, which may influence future investment strategies and market trends.
Continue Reading
Planet Labs PBC Secures Nine-Figure Deal with Swedish Armed Forces, Shares Surge 7%
- Stock Surge: Planet Labs PBC's announcement of a multi-year nine-figure agreement with the Swedish Armed Forces led to a 7% increase in share price to $24.29 on Monday, reflecting strong market confidence in the company's long-term contracts.
- Revenue Outlook Boost: Day One Biopharmaceuticals Inc reported preliminary 2025 OJEMDA net product revenue of $155.4 million, up 172% year-over-year, indicating robust growth potential in the biopharmaceutical sector that may attract more investor interest.
- Market Dynamics: Amid a broader decline in U.S. stocks, Wheels Up Experience Inc saw its shares jump 30.2% to $0.89, suggesting a market reassessment of its business model, potentially providing support for future financing and expansion.
- Increased Demand for Safe Assets: Growing concerns about Federal Reserve independence have led investors to shift towards safe-haven assets like gold, driving up precious metals stocks, which reflects market sensitivity to economic uncertainties and a preference for secure investments.
Continue Reading